Substance / Medication

Idarubicin

Overview

Active Ingredient
idarubicin
RxNorm CUI
5650

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Mayer Karin, Hahn-Ast Corinna, Schwab Katjana et al. · Eur J Haematol · 2020
PMID: 32049382Meta-Analysis
Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige Sunil, Lapidus Rena G, Carter-Cooper Brandon A et al. · Cancer Chemother Pharmacol · 2019
PMID: 30968179Meta-AnalysisFull text (PMC)
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.
Owattanapanich Weerapat, Owattanapanich Natthida, Kungwankiattichai Smith et al. · Clin Lymphoma Myeloma Leuk · 2018
PMID: 30241991Meta-Analysis
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Sekine Leo, Morais Vinícius Daudt, Lima Karine Margarites et al. · Hematol Oncol · 2015
PMID: 25363800Meta-Analysis
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li Xi, Xu ShuangNian, Tan Ya et al. · Cochrane Database Syst Rev · 2015
PMID: 26037486Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Idarubicin (substance)
SNOMED CT
372539000
UMLS CUI
C0020789
RxNorm CUI
5650

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.